Department of Immunology, Weizmann Institute of Science, Rehovot 76100, Israel.
Nat Rev Immunol. 2017 Apr;17(4):219-232. doi: 10.1038/nri.2017.7. Epub 2017 Mar 6.
Throughout the past century, we have seen the emergence of a large number of multifactorial diseases, including inflammatory, autoimmune, metabolic, neoplastic and neurodegenerative diseases, many of which have been recently associated with intestinal dysbiosis - that is, compositional and functional alterations of the gut microbiome. In linking the pathogenesis of common diseases to dysbiosis, the microbiome field is challenged to decipher the mechanisms involved in the de novo generation and the persistence of dysbiotic microbiome configurations, and to differentiate causal host-microbiome associations from secondary microbial changes that accompany disease course. In this Review, we categorize dysbiosis in conceptual terms and provide an overview of immunological associations; the causes and consequences of bacterial dysbiosis, and their involvement in the molecular aetiology of common diseases; and implications for the rational design of new therapeutic approaches. A molecular- level understanding of the origins of dysbiosis, its endogenous and environmental regulatory processes, and its downstream effects may enable us to develop microbiome-targeting therapies for a multitude of common immune-mediated diseases.
在过去的一个世纪里,我们见证了大量多因素疾病的出现,包括炎症性、自身免疫性、代谢性、肿瘤性和神经退行性疾病,其中许多疾病最近与肠道菌群失调有关——即肠道微生物组的组成和功能改变。在将常见疾病的发病机制与菌群失调联系起来的过程中,微生物组领域面临着破译新生成和持续存在的菌群失调结构所涉及的机制的挑战,并区分与疾病过程相伴的继发微生物变化相关的因果宿主-微生物关联。在这篇综述中,我们从概念上对菌群失调进行分类,并概述免疫关联;细菌菌群失调的原因和后果,以及它们在常见疾病的分子发病机制中的作用;并为新的治疗方法的合理设计提供了启示。对菌群失调的起源、其内在和环境调节过程以及下游效应的分子水平理解,可能使我们能够针对多种常见的免疫介导性疾病开发针对微生物组的治疗方法。